Jeff Parke, founder and executive director of Cold Ischemia Foundation, is calling for careful evaluation of BHOC and open discussion of its potential role in oxygen delivery and organ sustainability.
In his LinkedIn post, the patient advocate and kidney transplant recipient explains why the foundation is exploring BHOC, Biological Hemoglobin Oxygen Carrier. He focuses on what research shows, what remains unanswered, and what the technology could contribute to organ preservation and perfusion.
“Innovation deserves serious examination, not automatic acceptance or reflexive dismissal.”
Jeff Parke
Parke calls for reliable information, transparency and scrutiny of safety and effectiveness. He makes a clear distinction between potential benefits and established outcomes.
At BHOC Transplant, we welcome this discussion. The experience of patients and care partners helps keep research focused on the people it is intended to serve.
